 BeiGene Ltd. BGNE, 0.25 said Monday it had entered an agreement with Swiss drug company Novartis Pharma AG NVS, -0.20 to develop its investigational TIGIT inhibitor ociperlimab in North America, Europe, and Japan and to market five Novartis oncology treatments in China. 